<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":4186,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Marsh v. Genentech, Inc., 693 F.3d 546 (6th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/91e42e2acceda92276e862ad77f21a65'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/91e42e2acceda92276e862ad77f21a65'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1IOEAQ003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1IOEAQ003">Previous Result: <span>Wilson v. Metals USA, Inc., NO. CIV. S-1...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1IOEBG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1IOEBG003">Next Result: <span>Children&#x27;s Hosp. &amp; Research Ctr. Oakland...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Marsh v. Genentech, Inc., 693 F.3d 546 (6th Cir. 2012), Court Opinion'>
Marsh v. Genentech, Inc., 693 F.3d 546 (6th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Marsh v. Genentech, Inc., 693 F.3d 546 (6th Cir. 2012), Court Opinion</div>
<div class='docId'>X1I6S3I003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Marsh v. Genentech, Inc.</div>
<div class='displayCitation'>2012 BL 227341</div>
<div class='displayCitation'>2012 BL 227343</div>
<div class='displayCitation'>2012 BL 227347</div>
<div class='displayCitation'>2012 BL 230937</div>
<div class='displayCitation'>693 F.3d 546</div>
<div class='displayCitation'>bna a0d4m6z3g6</div>
<div class='displayCitation'>wkf6case:26327097</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I6S3I003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Marsh v. Genentech, Inc., 693 F.3d 546 (6th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Marsh v. Genentech, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1I6S3I003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I6S3I003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I6S3I003" /><input id="title" name="title" type="hidden" value="Marsh v. Genentech, Inc., 693 F.3d 546 (6th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="91e42e2acceda92276e862ad77f21a65" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I6S3I003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%39%31e%34%32e%32acceda%39%32%32%37%36e%38%36%32ad%37%37f%32%31a%36%35%2Fdocument%2FX%31I%36S%33I%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/bcite/X1I6S3I003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/bcite/X1I6S3I003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/bcite/X1I6S3I003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/related_content/X1I6S3I003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1725372628995";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">693 F.3d 546</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 11-2373, 11-2385, 11-2417, 11-2419.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 227343</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Sixth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
Vicki MARSH, The Estate of Shay Blair, by personal representative Trisharla
Brown, David Tiefenthal, and The Estate of Eddie A. Muniz, by personal
representative Sheila Muniz, Plaintiffs-Appellants, v. GENENTECH, INC. and
Xoma (U.S.) LLC, Defendants-Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 11-2373, 11-2385, 11-2417, 11-2419.
</center></p>
<p><center>
Argued: July 20, 2012.
</center></p>
<p><center>
Decided and Filed: September 6, 2012. Rehearing and Rehearing En Banc Denied
October 12, 2012.
</center></p>
<div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Eastern District of
Michigan, Robert H. Cleland, J.
<span CLASS="page_no" data-cite="693 f 3d 547" data-cite-type="PrimaryFederalReporter" data-cite-pageno="547" data-primary-citation="693 F.3d 546">[*547]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<span CLASS="page_no" data-cite="693 f 3d 548" data-cite-type="PrimaryFederalReporter" data-cite-pageno="548" data-primary-citation="693 F.3d 546">[*548]</span> <div id="para2" printdualcolumn="true"><p>
<b>ARGUED:</b> Alyson Oliver, Kresch Oliver PLLC, Southfield, Michigan, for
Appellants. Richmond T. Moore, Williams &amp; Connolly LLP, Washington, D.C.,
for Appellees. <b>ON BRIEF:</b> Alyson Oliver, Kresch Oliver PLLC, Southfield,
Michigan, for Appellants. Richmond T. Moore, Jennifer N. Wimsatt Pusateri,
Williams &amp; Connolly LLP, Washington, D.C., for Appellees.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before: SILER and MOORE, Circuit Judges; VAN TATENHOVE, District Judge.<a HREF="#fn*00" name="fnref_fn*00">[fn*]</a>
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span class="fr"><a HREF="#fnref_fn*00" name="fn*00">[fn*]</a></span> The Honorable Gregory F. Van Tatenhove, United States District Judge
for the Eastern District of Kentucky, sitting by designation.
</p></div>
<div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>OPINION</b>
</p></div></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  KAREN NELSON MOORE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Vicki Marsh, Shay Blair, David Tiefenthal, and the Estate of Eddie Muniz
(collectively, "Marsh"), the plaintiffs in these consolidated
products-liability actions, brought suit against drug manufacturers
Genentech, Inc. and Xoma (U.S.) LLC (collectively, "Genentech") to recover
for injuries allegedly sustained from use of the psoriasis medication
Raptiva. The district court granted Genentech's motion to dismiss, holding
that Genentech was entitled to immunity under the Michigan Products
Liability Act (the Act) and that Marsh's claim that immunity did not apply
was preempted by federal law. Because the allegations underlying Marsh's
argument that immunity does not apply are essentially the type of claim that
Supreme Court and Sixth Circuit precedent holds is preempted, we AFFIRM.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>I. BACKGROUND</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Genentech designed, manufactured, and sold the psoriasis medication
Raptiva, which was approved by the federal Food and Drug Administration
("FDA") in 2003 and sold in the United States from 2003 until 2009. Raptiva
works by suppressing T-cells to prevent them from migrating to the skin and
causing psoriasis. Because T-cells help fight infections, however, their
suppression has the potential to cause potentially life-threatening side
effects. Following reports of adverse health effects, including a rare brain
infection, in patients treated with Raptiva, Genentech voluntarily removed
Raptiva from the market in 2009.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marsh began using Raptiva in 2004 and subsequently suffered viral
meningitis and a collapsed lung; she attributes these conditions to her use
of Raptiva.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> She brought suit against Genentech in 2011, alleging strict
products liability under design-defect and failure-to-warn theories,
negligence, breach of warranty, and fraud. She contends that, both prior to
and after FDA approval of Raptiva, Genentech knew of dangerous side effects
that it concealed from the public <span CLASS="page_no" data-cite="2012 bl 227343 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> and did not include in the drug's label.
Marsh also alleged that Genentech "intentionally and negligently failed to
update statement of contraindications, warnings, precautions, and adverse
reactions that Defendant affirmatively knew about" and "intentionally and
negligently failed to comply with various but not limited to, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ476003?jcsearch=21%20cfr%20pt%20201&amp;summary=yes#jcite">21 CFR 201</a>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ4BO003?jcsearch=21%20cfr%20pt%20202&amp;summary=yes#jcite">21 CFR 202</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ538003?jcsearch=21%20cfr%20314%2080&amp;summary=yes#jcite">21 CFR 314.80</a>, and <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ53A003?jcsearch=21%20cfr%20314%2081&amp;summary=yes#jcite">21 CFR 314.81</a>." R.1 (Marsh Complaint) at &para;&para;
110-111 (Page ID # 27).<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
<span CLASS="page_no" data-cite="693 f 3d 549" data-cite-type="PrimaryFederalReporter" data-cite-pageno="549" data-primary-citation="693 F.3d 546">[*549]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following a transfer of venue, Genentech moved to dismiss on the grounds
that it was immune from suit under the state Act, which provides that drug
manufacturers are not liable in products-liability actions if the allegedly
dangerous drug and its label were approved by the FDA and were in compliance
with the FDA's approval at the time that the drug left the manufacturer's
control. <i>See</i> Mich. Comp. Laws &sect; <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20600.2946(5)&amp;summary=yes#jcite">600.2946</a>(5). Marsh countered that Genentech
was not entitled to immunity because it failed to submit updated safety
information to the FDA after Raptiva had gone to market or otherwise comply
with various FDA regulations regarding post-marketing reporting, which was a
condition of FDA approval.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court granted Genentech's motion to dismiss, holding that
Genentech was immune from suit because neither statutory exception to
immunity for drug manufacturers &mdash; that the manufacturer had defrauded or
bribed the FDA &mdash; applied. Citing our decision in <i>Garcia v. Wyeth-Ayerst</i>
<i>Laboratories</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d 961</a> (6th Cir.2004), the district court explained that
federal law preempts tort claims premised on the Act's exceptions absent a
finding by the FDA itself that the manufacturer had committed fraud or
bribery. The district court concluded that, because Marsh had not alleged
that the FDA had found that Genentech committed fraud, her claim was
preempted. The district court subsequently denied Marsh's motion for
reconsideration. Marsh timely appealed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Marsh again contends that immunity does not apply because
Genentech's failure to submit updated safety information rendered Raptiva
non-compliant with the FDA's approval at the time it left Genentech's
control. Because her claim is premised on non-compliance rather than the
fraud exception, she argues that it is not preempted under <i>Garcia.</i> In
addition, she characterizes this suit as the type of state-law tort claim
that the Supreme Court held was not preempted in <i>Wyeth v. Levine</i>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. 555</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=173%20l%20ed%202d%2051&amp;summary=yes#jcite">173 L.Ed.2d 51</a> (2009). Finally, Marsh argues
that immunity is an affirmative defense and thus that the district court
erred by not requiring Genentech to prove Raptiva's compliance with the
FDA's approval after Marsh alleged non-compliance in the complaint.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In response, Genentech characterizes failure to submit safety update
reports as a species of fraud that falls within the Act's first exception
and is thus preempted absent a finding of fraud by the FDA. Alternatively,
Genentech argues that Marsh's claim is preempted under <i>Garcia</i> regardless of
how it is characterized.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>II. JURISDICTION AND STANDARD OF REVIEW</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have jurisdiction over this diversity action pursuant to
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEIMUQ003?jcsearch=28%20usc%201332&amp;summary=yes#jcite">28 U.S.C. &sect; 1332</a>. Both parties agree that Michigan law applies. We review
the district court'<span CLASS="page_no" data-cite="2012 bl 227343 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> s grant of Genentech's motion to dismiss de novo. <i>Brown</i>
<i>v. Cassens Transp. Co.</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1HEHG6003?jcsearch=675%20f%203d%20946&amp;summary=yes#jcite">675 F.3d 946</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1HEHG6003?jcsearch=675%20f%203d%20946&amp;summary=yes#jcite">953</a> (6th Cir.2012).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>III. ANALYSIS</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>A. Implied Preemption and Michigan Products-Liability Law</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Michigan's products-liability regime is statutory. A drug manufacturer or
seller is not liable for injuries caused by the use of its products "if the
drug was approved for safety and efficacy by the United States food and drug
administration, and the drug and its labeling were in compliance with the
United States food and drug administration's approval at the time the drug
left the control of the manufacturer or seller."
<span CLASS="page_no" data-cite="693 f 3d 550" data-cite-type="PrimaryFederalReporter" data-cite-pageno="550" data-primary-citation="693 F.3d 546">[*550]</span> 
is not defective or unreasonably dangerous" if such criteria are met. <i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20%20600.2946(5)&amp;summary=yes#jcite">Id</a>.</i>
Statutory immunity does not apply, however, if the manufacturer or seller:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) Intentionally withholds from or misrepresents to the United
    States food and drug administration information concerning the drug
    that is required to be submitted under the federal food, drug, and
    cosmetic act, chapter 675, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=52%20stat%201040&amp;summary=yes#jcite">52 Stat. 1040</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5LU003?jcsearch=21%20usc%20301&amp;summary=yes#jcite">21 U.S.C. 301</a> to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5M2003?jcsearch=21%20U.S.C.%20321&amp;summary=yes#jcite">321</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5MC003?jcsearch=21%20U.S.C.%20331&amp;summary=yes#jcite">331</a>
    to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5NC003?jcsearch=21%20U.S.C.343-2&amp;summary=yes#jcite">343-2</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5NI003?jcsearch=21%20U.S.C.%20344&amp;summary=yes#jcite">344</a> to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5NO003?jcsearch=21%20U.S.C.%20346a&amp;summary=yes#jcite">346a</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5NS003?jcsearch=21%20U.S.C.%20347&amp;summary=yes#jcite">347</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5O2003?jcsearch=21%20U.S.C.%20348&amp;summary=yes#jcite">348</a> to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5OK003?jcsearch=21%20U.S.C.%20353&amp;summary=yes#jcite">353</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5OQ003?jcsearch=21%20U.S.C.%20355&amp;summary=yes#jcite">355</a> to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5PC003?jcsearch=21%20U.S.C.%20360&amp;summary=yes#jcite">360</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XEI5PG003?jcsearch=21%20U.S.C.%20360b&amp;summary=yes#jcite">360b</a> to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X197632003?jcsearch=21%20U.S.C.%20376&amp;summary=yes#jcite">376</a>, and
    <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X197636003?jcsearch=21%20U.S.C.%20378&amp;summary=yes#jcite">378</a> to <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X19765U003?jcsearch=21%20U.S.C.%20395&amp;summary=yes#jcite">395</a>, and the drug would not have been approved, or the United
    States food and drug administration would have withdrawn approval
    for the drug if the information were accurately submitted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
or
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) Makes an illegal payment to an official or employee of the
    United States food and drug administration for the purpose of
    securing or maintaining approval of the drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Id.</i> The Michigan Supreme Court has described the Act's immunity provision as
"an absolute defense to a products liability claim" premised on the
determination that "compliance with federal governmental standards
(established by the FDA) is conclusive on the issue of due care for drugs."
<i>Taylor v. Smithkline Beecham Corp.</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XAFP1M?jcsearch=468%20michigan%201&amp;summary=yes#jcite">468 Mich. 1</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XAFP1M?jcsearch=658%20north%20western%202d%20127&amp;summary=yes#jcite">658 N.W.2d 127</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XAFP1M?jcsearch=658%20north%20western%202d%20127&amp;summary=yes#jcite">130-31</a>
(2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Garcia</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d at 965-66</a>, we held that federal law impliedly preempts
the Act's two exceptions.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> In so holding, we relied on <i>Buckman Co. v.</i>
<i>Plaintiffs' Legal Committee</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. 341</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=148%20l%20ed%202d%20854&amp;summary=yes#jcite">148 L.Ed.2d 854</a>
(2001), in which the Supreme Court held that the federal Food, Drug, and
Cosmetic Act ("FDCA") impliedly preempts state-law fraud-on-the-FDA
claims.<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The plaintiffs in <i>Buckman</i> brought suit against a medical-device
manufacturer under state law, alleging that the manufacturer had made
fraudulent representations to the FDA in the course of the approval process
and that, as a result, the device was improperly placed on the market.
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 346-47</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. The Court held that such claims are
preempted because they interfere with the federal regulatory scheme for the
approval of drugs and medical devices, <i></i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">id. at 348-50</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, and
because they implicate the "inherently federal" issue of "the relationship
between a federal agency and the entity it regulates," <i></i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">id. at 347</a>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. Indeed, because "[p]olicing fraud against federal agencies
is hardly `a field which the States have traditionally occupied,'" the
traditional presumption against preemption did not apply. <i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id</a>.</i> (quoting <i>Rice</i>
<i>v. Santa Fe Elevator Corp.</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X5C15A?jcsearch=331%20us%20218&amp;summary=yes#jcite">331 U.S. 218</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X5C15A?jcsearch=331%20us%20218&amp;summary=yes#jcite">230</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=67%20supreme%20court%201146&amp;summary=yes#jcite">67 S.Ct. 1146</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=91%20l%20ed%201447&amp;summary=yes#jcite">91 L.Ed. 1447</a>
(1947)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="693 f 3d 551" data-cite-type="PrimaryFederalReporter" data-cite-pageno="551" data-primary-citation="693 F.3d 546">[*551]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDCA sets forth a "comprehensive scheme" of disclosure requirements as
part of the approval process. <i>Id.</i> at 348, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. Along with these
requirements, the FDCA empowers the FDA to investigate and penalize fraud in
a manufacturer's disclosures or elsewhere in the approval process. <i>Id.</i> at
348-<span CLASS="page_no" data-cite="2012 bl 227343 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> 49, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. The Court viewed these provisions of the FDCA as
evidence that Congress intended exclusively federal enforcement. <i>Id.</i> at 352,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. State-law fraud-on-the-FDA claims would thus "inevitably
conflict with the FDA's responsibility to police fraud consistently with the
Administration's judgment and objectives" by allowing state courts to rule
on the adequacy of a manufacturer's disclosures. <i>Id.</i> at 350, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>.
These claims could also interfere with the FDA's approval process, because
the possibility that "disclosures to the FDA, although deemed appropriate by
the Administration, will later be judged insufficient in state court" could
lead manufacturers to oversubmit information and thus burden the evaluation
process. <i>Id.</i> at 351, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At its core, a fraud-on-the-FDA claim implicates "the relationship between
a federal agency and the entity it regulates," a relationship that is
"inherently federal in character." <i>Id.</i> at 347, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. Moreover, the
basis for the claim is violation of a federal statute or regulation. Unlike
a common-law tort claim, these "fraud claims exist solely by virtue of the
FDCA disclosure requirements." <i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id</a>.</i> at 352-53, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. The alleged
wrong is inadequate disclosure to a federal agency rather than breach of the
common-law duty to use reasonable care. <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following <i>Buckman</i>, we held in <i>Garcia</i> that suits against drug manufacturers
under Michigan law in which the plaintiff seeks to defeat immunity by
invoking the Act's fraud exceptions are equivalent to fraud-on-the-FDA
claims and are thus preempted. <i>Garcia</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d at 965-66</a>.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> Even though,
under Michigan law, fraud on the FDA is an exception to a grant of immunity
to the manufacturer rather than a stand-alone cause of action, it
nonetheless ultimately "requir[es] proof of fraud committed against the FDA"
to succeed. <i>Id.</i> (internal quotation marks omitted). <i>Garcia</i> thus essentially
requires treating a plaintiffs fraud arguments against manufacturer immunity
as a threshold "claim" that can be preempted.<a HREF="#fn600" name="fnref_fn600">[fn6]</a> We subsequently held that
<i>Garcia</i> applied to claims that the manufacturer misrepresented or withheld
information about a drug from the FDA after the FDA had approved it. <i>In re</i>
<i>Aredia &amp; Zometa Prods. Liab. Litig.</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=352%20f%20appx%20994&amp;summary=yes#jcite">352 Fed.Appx. 994</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XFPLMD?jcsearch=352%20f%20appx%20994&amp;summary=yes#jcite">995</a> (6th Cir.2009)
(unpublished opinion) (holding that such claims are preempted under the FDCA
"unless some federal agency has already found the requisite fraud on the
FDA").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Subsequent to <i>Buekman</i> and <i>Garcia</i>, the Supreme Court again dealt with the
implied preemptive effect of the FDCA on state-law tort claims against drug
manufacturers.
<span CLASS="page_no" data-cite="693 f 3d 552" data-cite-type="PrimaryFederalReporter" data-cite-pageno="552" data-primary-citation="693 F.3d 546">[*552]</span> 
In <i>Wyeth</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 558-59</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>, the Court held that a
state-law failure-to-warn claim premised on the inadequacy of a brand-name
drug's label was not preempted simply because the FDA had approved the
label. The manufacturer could still be liable under state law for failing to
update the drug's label based on newly acquired information. <i>See </i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=555%20U.S.%20555&amp;summary=yes#jcite">id. at 571</a>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>. Because Congress has not provided a federal cause of action
for consumers harmed by unsafe drugs, state-law failure-to-warn claims
provide "an additional, and important, layer of consumer protection that
complements FDA regulation." <i></i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=555%20U.S.%20555&amp;summary=yes#jcite">Id. at 579</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>B. Compliance <span CLASS="page_no" data-cite="2012 bl 227343 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> With FDA Approval</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marsh would protest that the above analysis is an irrelevant detour,
because she does not invoke the Act's fraud exception. Instead, her argument
that immunity does not apply is premised on Genentech's alleged
non-compliance with the terms of the FDA's approval of Raptiva. Whatever
vitality this distinction might have in other circumstances, the nature of
Marsh's allegations of non-compliance does not take this case outside of
<i>Garcia's</i> precedential reach.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As described above, the state Act provides immunity from liability if "the
drug and its labeling were in compliance with the United States food and
drug administration's approval at the time the drug left the control of the
manufacturer or seller." Mich. Comp. Laws &sect; <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20%20600.2946(5)&amp;summary=yes#jcite">600.2946</a>(5). The Act does not
define "compliance with [FDA] approval," and the parties have not cited, and
we have not found, any Michigan caselaw interpreting this requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The nature of Marsh's allegations of non-compliance is somewhat obscure,
but she seems to allege that Genentech failed to comply with the FDA's
post-marketing reporting requirements. The complaint alleges that Genentech
"intentionally and negligently failed to update statement of
contraindications, warnings, precautions, and adverse reactions that
Defendant affirmatively knew about" and "intentionally and negligently
failed to comply with various but not limited to, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ476003?jcsearch=21%20cfr%20pt%20201&amp;summary=yes#jcite">21 CFR 201</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ4BO003?jcsearch=21%20cfr%20pt%20202&amp;summary=yes#jcite">21 CFR 202</a>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ538003?jcsearch=21%20cfr%20314%2080&amp;summary=yes#jcite">21 CFR 314.80</a>, and <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ53A003?jcsearch=21%20cfr%20314%2081&amp;summary=yes#jcite">21 CFR 314.81</a>." R.1 at &para;&para; 110-111 (Page <cite>ID</cite> # 27). Marsh
contends that these failures constitute non-compliance with the FDA's
approval because, as part of its application for approval of Raptiva,
Genentech signed FDA Form 356h, which requires the applicant to certify as
follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      "I agree to update this application with new safety information
    about the product that may reasonably affect the statement of
    contraindicaitons [sic], warnings, precautions or adverse reactions
    in the draft labeling. I agree to submit safety update reports as
    provided for by regulation or as requested by the FDA. If this
    application is approved, I agree to comply with all applicable laws
    and regulations that apply to approved applications. . . ."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><cite>Id. &para; 108</cite> (Page <cite>ID</cite> # 27).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Such allegations do not fit comfortably within the statutory language
requiring compliance for immunity to apply. Marsh's complaint alleges that
<i>Genentech</i> did not comply with the terms of the FDA approval by failing to
update its application or submit safety reports, not that "the drug and its
labeling" did not comply. Mich. Comp. Laws &sect; <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20%20600.2946(5)&amp;summary=yes#jcite">600.2946</a>(5); <i>see also Taylor</i>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XAFP1M?jcsearch=658%20north%20western%202d%20127&amp;summary=yes#jcite">658 N.W.2d at 129-30</a> (explaining that the Act limits a manufacturer's
liability when "the drug at issue was . . . labeled in compliance with FDA
standards"). Put another way, the statutory language suggests that immunity
requires substantive compliance with FDA approval, but Marsh essentially
alleges procedural non-compliance. Marsh does not allege that the dose
<span CLASS="page_no" data-cite="693 f 3d 553" data-cite-type="PrimaryFederalReporter" data-cite-pageno="553" data-primary-citation="693 F.3d 546">[*553]</span> 
of Raptiva she received was adulterated or that its label varied from the
label that the FDA approved.<a HREF="#fn700" name="fnref_fn700">[fn7]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, failure to submit reports to the FDA that the FDA requires is
arguably a species of fraud on the agency under the state Act. Indeed, the
Michigan <span CLASS="page_no" data-cite="2012 bl 227343 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> Act's fraud exception specifically encompasses at least some of the
misconduct Marsh alleges &mdash; a manufacturer "[i]ntentionally withhold[ing]
from . . . the [FDA] information concerning the drug that is required to be
submitted under the [FDCA]" when the FDA "would have withdrawn approval for
the drug if the information were accurately submitted." <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20%20600.2946(5)(a)&amp;summary=yes#jcite">Mich. Comp. Laws &sect;
600.2946(5)(a)</a>.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  If Marsh's allegations do constitute non-compliance within the meaning of
the Act, her "claim" that immunity does not apply triggers the same concerns
that animated <i>Buckman</i> and <i>Garcia.</i> Marsh alleges that Genentech failed to
submit updated safety information to the FDA as required of all applicants
by FDA Form 356h and generally applicable FDA regulations, and thus relies
on "federal enactments [a]s a critical element in [her] case." <i>Buckman</i>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 353</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. Moreover, this alleged wrong was
perpetrated upon the agency, and thus implicates the "inherently federal"
relationship described in <i>Buckman. </i><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id. at 347</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. Finally,
Marsh's suit would require a court to rule on the adequacy of Genentech's
post-marketing disclosures to the FDA, which is the kind of "inter-branch[]
peddling" that concerned the Court in <i>Buckman. See Garcia</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d at 966</a>.
The FDA regulates post-marketing reporting, requiring manufacturers to
report, inter alia, "adverse drug experience information,"
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ538003?jcsearch=21%20C.F.R.%20%20314.80(c)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.80</a>(c), and "significant new information . . . that might
affect the safety, effectiveness, or labeling of the drug product," <i><cite>id</cite>.</i> <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ53A003?jcsearch=21%20C.F.R.%20%20314.81(b)(2)(i)&amp;summary=yes#jcite">&sect;
314.81(b)(2)(i)</a>. The FDA also has the discretionary authority to withdraw
approval of a drug based on failure to submit these reports. <i><cite>Id</cite>.</i> &sect;
314.80CJ), 314.81(d). Having a court
<span CLASS="page_no" data-cite="693 f 3d 554" data-cite-type="PrimaryFederalReporter" data-cite-pageno="554" data-primary-citation="693 F.3d 546">[*554]</span> 
determine whether any non-disclosed information "`may reasonably affect the
statement of contraindications, warnings, precautions or adverse reactions
in the draft labeling,'" R.1 at &para; 108 (Page ID #27) (quoting FDA Form 356h),
would both usurp the agency's role and go beyond the court's institutional
expertise.<a HREF="#fn900" name="fnref_fn900">[fn9]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The fact that Marsh's substantive claims sound in negligence and strict
products liability would not enable her to avoid preemption, because so did
the claims in <i>Garcia.</i> Marsh alleges that Raptiva was "defective and
unreasonably dangerous," R.1 &para; 128 (Page ID #30), but Michigan has concluded
that a drug that is approved by the FDA and is in compliance with that
approval is, as a matter of law, "not defective or unreasonably dangerous,"
Mich. Comp. Laws &sect; <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20%20600.2946(5)&amp;summary=yes#jcite">600.2946</a>(5). In order to reach her substantive claim
under Michigan law, Marsh must first defeat immunity, and, as noted above,
<i>Garcia</i> essentially treats this task as a threshold claim that can be
preempted. Although Marsh's allegations of failure to report are a "claim"
against immunity rather than the substantive basis of her tort claim, <i>Garcia</i>
conflates the two for preemption purposes; under <i>Garcia</i>, the nature of
Marsh's underlying substantive claim is immaterial to the preemption
analysis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Marsh attests that her claim, like the failure-to-warn claim in
<i>Wyeth</i>, complements rather than conflicts with the FDA's regulatory regime
and thus survives preemption. This argument confuses the validity of her
substantive claim <span CLASS="page_no" data-cite="2012 bl 227343 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> with the validity of her argument that immunity does not
apply. Marsh is correct that <i>Wyeth</i> preserves a role for state law in
post-marketing enforcement of drug safety; as a general matter, FDA approval
of a drug label does not preempt a state common-law failure-to-warn suit
premised on the claim that the FDA-approved label is nonetheless inadequate.
<i>See Wyeth</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 558-59</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>. Absent the Michigan Act's
immunity provision, Marsh could bring such a claim. <i>Wyeth</i> does not help
plaintiffs in Michigan, however. Although preemption principles do not
foreclose state-law failure-to-warn claims once the FDA has approved a drug,
Michigan law does so. Absent a successful "claim" that immunity does not
apply, the Act prevents Michigan plaintiffs from recovering on the type of
claim brought by the plaintiff under Vermont law in <i>Wyeth.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>C. Affirmative Defense</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marsh argues that immunity is an affirmative defense and thus that the
district court should have required Genentech to prove that the dose of
Raptiva that Marsh received was in compliance with the FDA's approval when
it left Genentech's control before granting immunity to Genentech. Marsh
does not cite any authority for the proposition that immunity under the Act
is an affirmative defense, but we will assume for present purposes that it
is.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  If immunity is an affirmative defense, a defendant manufacturer would
normally bear the burden of proving that the FDA approved the allegedly
defective drug and that the drug was in compliance with that approval when
it left the manufacturer's control. A motion to dismiss
<span CLASS="page_no" data-cite="693 f 3d 555" data-cite-type="PrimaryFederalReporter" data-cite-pageno="555" data-primary-citation="693 F.3d 546">[*555]</span> 
can be premised on an affirmative defense, however, if "the plaintiffs own
allegations show that a defense exists that legally defeats the claim for
relief." 5B Charles Alan Wright, Arthur Miller, Mary Kay Kane &amp; Richard
Marcus, Federal Practice &amp; Procedure <cite>&sect; 1357</cite> at 713 (3d ed. 2004). Here,
Marsh's complaint quoted the Act's immunity provision and preemptively
alleged non-compliance in order to defeat immunity. After setting forth the
allegations that Genentech failed to submit updated safety information, the
complaint concludes that "[a]s Raptiva was not in compliance with the United
States food and drug administration's approval at the time it left the
control of the Defendant, Mich. Comp. Laws &sect; <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XM64AQ003?jcsearch=Mich.%20Comp.%20Laws%20%20600.2946(5)&amp;summary=yes#jcite">600.2946</a>(5) will not shield the
Defendants from liability in this action." R.1 at &para; 112 (Page <cite>ID</cite> # 28)
(capitalization omitted). In her response to Genentech's motion to dismiss,
Marsh references these allegations and states that she "has pled that
Raptiva was not in compliance with its approval at the time it left
Defendants control." R.15 at 13 (Page <cite>ID</cite> # 97).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although the fact that "the plaintiff merely has anticipated the
defendant's answer and tried to negate a defense he believes his opponent
will attempt to use against him" is generally not enough to merit dismissal
based on an affirmative defense, 5B Wright &amp; Miller, Federal Practice &amp;
Procedure <cite>&sect; 1357</cite> at 713, Marsh anticipated the defense of immunity in a way
that shows that her response to the defense lacks merit. The complaint makes
clear that Marsh could not defeat <span CLASS="page_no" data-cite="2012 bl 227343 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> Genentech's arguments for immunity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>IV. CONCLUSION</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The State of Michigan has decided to limit the availability of tort
remedies against drug manufacturers. As a federal court sitting in
diversity, we are of course required to apply Michigan law. We are also
bound by our precedent interpreting that law. Even characterized as
non-compliance, Marsh's "claim" that Genentech is not entitled to immunity
under the Act triggers the same concerns that animated <i>Buckman</i> and <i>Garcia</i> &mdash;
it is premised on violation of federal law, implicates the relationship
between a federal agency and the entity it regulates, and asks the court to
assume a role usually held by the FDA &mdash; and is thus preempted. We AFFIRM the
judgment of the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Blair and Tiefenthal used Raptiva in 2006-2008 and 2007-2008,
respectively. Both developed lymphoma in 2008. Muniz used Raptiva in 2007
and died of kidney and liver failure later that year.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> With the exception of factual allegations related to each plaintiff's
use of Raptiva and adverse health effects, the four complaints are
identical. We follow both the parties' briefs and the district court in
citing Marsh's complaint.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> We also held that the Act's exceptions are not preempted when the FDA
itself has determined that the manufacturer committed fraud or bribery.
Because Marsh does not contend that the FDA made such a determination, this
aspect of <i>Garcia</i> has no bearing on this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> As relevant for this case, federal law impliedly preempts a state law
if the state law "creates an unacceptable `obstacle to the accomplishment
and execution of the full purposes and objectives of Congress.'" <i>Wyeth</i>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 563-64</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a> (quoting <i>Hines v. Davidawitz</i>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X2N5PE?jcsearch=312%20us%2052&amp;summary=yes#jcite">312 U.S. 52</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X2N5PE?jcsearch=312%20us%2052&amp;summary=yes#jcite">67</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X2N5PE?jcsearch=61%20supreme%20court%20399&amp;summary=yes#jcite">61 S.Ct. 399</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X2N5PE?jcsearch=85%20l%20ed%20581&amp;summary=yes#jcite">85 L.Ed. 581</a> (1941)). The Supreme Court has
identified two "cornerstones of . . . pre-emption jurisprudence": "First,
the purpose of Congress is the ultimate touchstone in every pre-emption
case. Second, in all preemption cases, and particularly in those in which
Congress has legislated in a field which the States have traditionally
occupied, we start with the assumption that the historic police powers of
the States were not to be superseded by the Federal Act unless that was the
clear and manifest purpose of Congress." <i>Id.</i> at 565, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>
(internal quotation marks, citations, and alterations omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> We also held that the fraud exceptions are not preempted "when the
federal agency itself determines that fraud marred the regulatory-approval
process." <i>Garcia</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XFPLMD?jcsearch=385%20F.3d%20961&amp;summary=yes#jcite">385 F.3d at 966</a>. Accordingly, "claims based on federal
findings of bribery or fraud on the FDA" can defeat manufacturer immunity
under the state Act. <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> At oral argument, Marsh cited the Second Circuit's opinion in <i>Desiano</i>
<i>v. Warner-Lambert &amp; Co.</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=467%20f%203d%2085&amp;summary=yes#jcite">467 F.3d 85</a> (2d Cir.2007), <i>aff'd by an equally</i>
<i>divided court sub nom. Warner-Lambert Co. v. Kent</i>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X18JA02003?jcsearch=552%20us%20440&amp;summary=yes#jcite">552 U.S. 440</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X18JA02003?jcsearch=552%20us%20440&amp;summary=yes#jcite">441</a>,
<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/1?citation=128%20supreme%20court%201168&amp;summary=yes#jcite">128 S.Ct. 1168</a>, <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X18JA02003?jcsearch=170%20l%20ed%202d%2051&amp;summary=yes#jcite">170 L.Ed.2d 51</a> (2008), which held that the Michigan Act's
exceptions were not preempted because, unlike in a stand-alone
fraud-on-the-FDA claim, plaintiffs' claims under the Act are traditional
tort claims that do not contain fraud as an element. We are, of course,
bound by our own published precedent in <i>Garcia</i> to the contrary.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> The complaint's C.F.R. citations support this view of Marsh's
allegations. Sections 314.80 and <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ53A003?jcsearch=21%20CFR%20314.81&amp;summary=yes#jcite">314.81</a> set forth post-marketing reporting
requirements. <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ476003?jcsearch=21%20C.F.R.%20201&amp;summary=yes#jcite">Section 201</a> governs labeling, which would seem more relevant,
but that section has seven subparts and seventy-one subsections, and Marsh
does not specify with which regulation therein Genentech failed to comply.
In her response to Genentech's motion to dismiss, Marsh attempted to
clarify, stating that "Plaintiffs allege post-<b><i>marketing</i></b> failure to warn" and
"<a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ476003?jcsearch=21%20C.F.R.%20201&amp;summary=yes#jcite">21 C.F.R. 201</a> covers warnings and therefore, a failure to warn is a failure
to comply with 21 C.F.R. 201." R.15 at 16 (Pl's Resp. to Defs.' Mot. to
Dismiss) (Page <cite>ID</cite> # 100). If Marsh means failure to warn consumers or
physicians with an adequate label, this action does not constitute
non-compliance if the FDA has approved the label. If she means failure to
"warn" the FDA by reporting new safety information, she is essentially
reiterating her allegation of noncompliance with the FDA's reporting
requirements. <a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/XMJ4BO003?jcsearch=21%20CFR%20202&amp;summary=yes#jcite">Section 202</a> poses a similar problem; that section governs
advertising, which, like the regulations governing post-marketing reporting,
does not go to the issue of whether a drug itself complies with the terms of
FDA approval.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> The district court interpreted Marsh's argument as an allegation of
fraud. Marsh's contention on appeal that the district court ignored the
Act's requirement of compliance with the FDA's approval or held that
immunity does not apply only if non-compliance was intentional rather than
negligent stems from a misreading of the district court's opinion. The
district court never held that a drug's compliance with FDA approval is not
a condition precedent to immunity for the manufacturer under the Act, but
instead concluded that Marsh was not alleging non-compliance. Nor did the
district court hold that only intentional fraud, rather than negligence,
could result in a finding of non-compliance. Such a holding would be
incorrect. Because the district court did not believe that the
non-compliance element was implicated, however, its ruling did not address
what is required for a showing of non-compliance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> Because the only alleged act of non-compliance in this case is the
manufacturer's failure to comply with generally applicable requirements of
disclosure to the agency, we take no position as to whether an allegation of
substantive non-compliance that is unique to the terms of approval of a
particular drug or that more directly involves a consumer, such as a
chemical variance or an inaccurate label, would be preempted under <i>Garcia.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
We also note that, as in <i>Garcia</i>, a claim of non-compliance based on failure
to submit safely update reports would not be preempted if the FDA itself had
found that the manufacturer had failed to report.
</p></div>
<!--BBLS DD 1725372628995-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I6S3I003/history">Direct History (5)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I6S3I003/analysis">Case Analysis (7)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I6S3I003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
7
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1Q6M265FC82">11-02373 (6th Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1Q6M27NQL82">11-02385 (6th Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1Q6M2CEV882">11-02417 (6th Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/91e42e2acceda92276e862ad77f21a65/document/X1Q6M2CL5SO2">11-02419 (6th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Products Liability</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/91e42e2acceda92276e862ad77f21a65/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "91e42e2acceda92276e862ad77f21a65";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY9b5fc1&previousPageId=&previousActivityInstanceId=ENTITY11fb56&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:20:51-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I6S3I003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY11fb56&previousPageId=&previousActivityInstanceId=ENTITY29d70e&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:20:47-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I6S3I003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I6S3I003";
$('#page_loader').show().spin();
JUDGE_IDS=["3028396"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
